Kala Pharmaceuticals (KALA) Tops Q2 EPS by 6c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q2 EPS of ($0.38), $0.06 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $2.02 million.

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Universal Logistics Holdings, Inc. (ULH) Tops Q1 EPS by 136c
• Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance